ELISpot and FluoroSpot Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The ELISpot and FluoroSpot Assay Market is segmented by Product (Analyzers, Assay Kits, and Ancillary Products), Application, End User, and Geography

Market Snapshot

 ELISpot and FluoroSpot Assay Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.3 %
 ELISpot and FluoroSpot Assay Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors attributing to the growth of the ELISpot and FluoroSpot assay market are the rising vaccine research to tackle the drug-resistant strains challenge, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits which is assessed to upsurge the market growth for ELISpot and FluoroSpot assay. 

ELISpot is a crucial path to vaccine development for many illnesses, namely AIDS, tuberculosis, HIV, malaria, cancer, and flu. The ELISpot test is among the most widely utilized immunoassays in clinical studies to assess vaccine. This reputation was based mainly on the higher sensitivity of the sample, statistical read-out, and ease of use in both large screening and individual tests. In fact, the test can be used to assess both T-cell reactions and vaccine-specific antibody-producing B cells.

Scope of the Report

As per the scope of the report, FluroSpot and ELISpot are commonly used with the use of fluorophores marked detection reagents for the realistic analysis of the immune system at the single-cell level. The FluoroSpot assay integrates ELISpot's sensitivity with the ability to concurrently analyze multi-analyte secretion, allowing cell population studies with different operational characteristics.

By Product
Assay kits
Ancillary Products
By End User
Hospitals & Clinical labs
Biopharmaceutical Company
Research Institutes
By Application
Vaccine Development
Clinical Trials
Cancer Research
Infectious Disease
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market

Dominant share is retained by the assay kits segment owing to the factors such as a high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies. 

As per the (WHO) World Health Organization, the main chronic illnesses presently make up nearly 60% of all fatalities and 43% of the worldwide disease burden. Their contribution is projected to increase up to 73% of all fatalities by 2020 and 60% of the worldwide morbidity. In addition, in developing countries, 79 percent of the deaths take place owing to chronic diseases. Furthermore, the technological innovation of assay kits and analyzers for ELISpot and FluoroSpot is also expected to drive the market growth.

 ELISpot and FluoroSpot Assay Market Key Trends

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall ELISpot and FluoroSpot assay market, throughout the forecast period. This is owing to factors such as the rising prevalence of chronic disorders such as infectious diseases and the geriatric population. 

An estimated 45 percent or about 33 million Americans were diagnosed with at least one chronic disease, according to the National Center for Biotechnology Information (NCBI), which is further expected to upsurge the demand of ELISpot and FluoroSpot assay in coming years.

 ELISpot and FluoroSpot Assay Market Growth by Region

Competitive Landscape

The ELISpot and FluoroSpot assay market is moderately competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe. 

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Chronic Diseases

      2. 4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of alternative detection technologies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Analyzers

      2. 5.1.2 Assay kits

      3. 5.1.3 Ancillary Products

    2. 5.2 By End User

      1. 5.2.1 Hospitals & Clinical labs

      2. 5.2.2 Biopharmaceutical Company

      3. 5.2.3 Research Institutes

    3. 5.3 By Application

      1. 5.3.1 Research

        1. Vaccine Development

        2. Clinical Trials

        3. Cancer Research

      2. 5.3.2 Diagnostics

        1. Infectious Disease

        2. Transplants

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Becton, Dickinson and Company

      2. 6.1.2 U-Cytech Biosciences

      3. 6.1.3 Cellular Technologies Limited

      4. 6.1.4 Mabtech AB

      5. 6.1.5 Abcam

      6. 6.1.6 Autoimmun Diagnostika GmbH

      7. 6.1.7 Lophius Biosciences GmbH

      8. 6.1.8 Bio-Connect B.V.

      9. 6.1.9 Oxford Immunotec

      10. 6.1.10 Bio-Techne Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The ELISpot and FluoroSpot Assay Market market is studied from 2018 - 2026.

The ELISpot and FluoroSpot Assay Market is growing at a CAGR of 13.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Becton, Dickinson and Company, U-CyTech biosciences, Cellular Technologies Limited (CTL), Mabtech AB, Abcam are the major companies operating in ELISpot and FluoroSpot Assay Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!